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Abstract
The outcomes from recent high profile deliberations concerning African health research and economic
development all point towards the need for a mechanism to support health innovation on the continent. The
mission of the African Network for Drugs and Diagnostics Innovation (ANDI), is to promote and sustain African-led
health product innovation to address African public health needs through the assembly of research networks, and
building of capacity to support human and economic development. ANDI is widely viewed as the vehicle to
implementing some of these recommendations. There is tremendous opportunity for Africa, to leverage the
expertise in natural products and traditional medicines in support of this objective to kick-start innovation. This
report highlights key recommendations that have emerged through expert forums convened by ANDI on the
challenges, opportunities and prospects for investing in this important area of research.
Background
The African Network for Drugs and Diagnostics Innova-
tion (ANDI) [1] was conceived and launched as a concept
at Abuja in 2008 by the World Health Organization
through TDR and its African and East Mediterranean
Regional Offices; several African institutions, policy
makers, Africans in the Diaspora, the African Develop-
ment Bank (AfDB) and other stakeholders. As a major
international partner, the European Union has also pro-
vided support, both through the EU Commission’s Eur-
opeAid Cooperation Office and through the EUs’ 7th
Framework Programme for research (FP7). Progress in
the past year on the establishment of ANDI has led to
the identification and selection of the United Nations
Economic Commission for Africa (UNECA) as the host
agency for ANDI in Africa[2]. ANDI intends to develop
and fund a portfolio of collaborative network projects
and leverage existing capacity in Africa in a manner that
will support capacity and infrastructural development for
product research, development and delivery. The key
objective is to discover, develop and deliver affordable
new drugs, vaccines, diagnostics and other health pro-
ducts (including those based upon natural products and
traditional medicines) to fight and prevent diseases that
disproportionately affect the African continent.
Over the past year, ANDI has convened its stakeholders
to discuss and debate mechanisms to advance R&D,
including those based on traditional medicines and natural
products, for diseases that afflict Africa, and how these
can be prioritized and implemented. This report provides
an overview of those discussions and the resulting recom-
mendations. It is important to note that although the dis-
ease focus of this special issue of the Malaria Journal on
natural products is clearly malaria, the issue of traditional
medicines is far more cross-cutting and goes beyond dis-
ease and/or specific research area.
Support for Traditional Medicine R&D in Africa
The MIM symposium
The 5th Multilateral Initiative for Malaria (MIM) Confer-
ence in Nairobi, Kenya (November 2-6, 2009), attracted
approximately 2,000 international delegates covering the
wide scope of research on malaria from malaria control,
treatment and efforts towards eradication, vector control
strategies, drug discovery & development activities and
vaccine discovery. During MIM, a joint symposium
between the European Union (EU) and WHO/TDR was
convened to define future research and development
needs in the field of drugs and diagnostics as part of the
work on ANDI. It also aimed at elaborating how EU’s 7th
framework programme (or successive programmes)
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might usefully contribute towards strengthening research
and development efforts to eliminate malaria in the long
term. Although the focus of the MIM meeting was
malaria, the product R& D and access challenges and
possible solutions discussed, in many ways cut across dis-
eases and are applicable to R&D activities in developing
countries, irrespective of the region. The symposium
attracted more than 100 participants that included
African and non-African researchers, funding and
research network organizations. A selection of varied
presentations covering drugs, diagnostics as well as nat-
ural products - based discovery, development and deliv-
ery placed the current situation in context and initiated a
very lively debate and discussions. The resulting consen-
sus document highlighted a number of priority research
areas. Excerpts from the report of relevance to the topics
of this special issue are:
Novel chemical entities
The paucity of novel chemical series to enter the devel-
opment pipeline for malaria and the neglected diseases
[3], was highlighted throughout the MIM conference.
This is indicative of the limited approaches and support
for preclinical drug discovery efforts. The need for
increased access to a broader collection of validated
drug or diagnostic targets; the exploration of broader
chemical space either through the assessment of natural
products, traditional medicines or synthesis of small
molecules; and repurposing of known drugs for other
indications were stressed at the meeting. A major issue
highlighted by several African scientists was how to bet-
ter advance natural products and traditional medicines
as a source of new drug leads and formulation. In this
context, it was agreed that the field of phytochemistry
required further development to support the discovery
of new chemical entities rather than just focusing on
publications as the final output. The need to encourage
and support well-coordinated multidisciplinary partner-
ships/networks to leverage available expertise was agreed
as the way forward. It was also agreed that a critical
mass of medicinal chemists, pharmacologists and toxi-
cologists were needed in Africa and strengthening these
areas would require more investment and coordinated
R&D in Africa through ANDI and other initiatives. Clin-
ical evaluation and registration of new products could
be pursued in collaboration with complimentary pro-
grams such as the European Developing Countries Clin-
ical Trial Partnership [4].
Traditional medicines
Could the next major breakthrough in malaria che-
motherapy come from natural products and traditional
medicines?, Will Africa be the source of such a break-
through? African researchers believe that Africa has a
lot to offer from its vast biodiversity resources that
could in effect provide answers to these questions, if
appropriate measures are taken. It is known from work
in Asia and South America that this indeed possible.
It is known that up to 80% of African populations use
traditional medicines in order to address their health issues
[5]. In spite of this, the biodiversity of Africa has yielded
few examples of standardized phytomedicines and only
limited systematic analysis of available medicinal plants
has been undertaken. Although some pharmaceutical pro-
ducts such as Niprisan? (for sickle cell anaemia) are com-
mercially available based on work done in Africa [6], more
work is required to develop a standard process for the eva-
luation and regulation of traditional medicines or any
resultant products. Many argue that this evaluation
requires modern product R&D processes such as biology,
computational methods, medicinal chemistry, DMPK as
well as toxicology, such that it should be possible to
develop standardized phytomedicines as it is done for
drugs based on synthetic compounds. A common argu-
ment is that the optimal efficacy of these plant-based pro-
ducts is inherently linked to the mixture of efficacious
chemical entities they contain and hence they should be
developed as both herbal formulations and also form the
basis of medicinal chemistry programmes. Concerted
efforts should be made to clearly define processes and
guidelines for traditional medicines and natural products
research, in order to support the advancement of this
important field. The development of traditional medicines
should not be seen as the answer to providing cheap treat-
ments to poor populations. It is important that such medi-
cines are given the same scrutiny as any other
pharmaceutical to ensure protection of patients from any
major adverse event and also to ensure the benefits of opti-
mal efficacy. Research in support of the use of traditional
medicines and natural products in disease prevention and
control should also receive attention, for example, vector
control. In all cases, consideration must be given to the
sustainable use of medicinal plants/natural products and
the conservation of the habitat in which they occur.
The workshop also identified enhanced efforts for
Health Systems research, and more R&D on diagnostics,
vaccines and enabling technologies as further priority
research areas for the African continent. All should be
tailored to support African priorities, needs and encou-
rage research leadership.
The 3rd ANDI Stakeholders Meeting
The recently concluded 3rd ANDI Stakeholders Meeting
(11-13 October 2010, United Nations Office in Nairobi,
Kenya) provided a forum for over 500 stakeholders from
40 countries to discuss progress made towards the imple-
mentation of the ANDI strategic business plan which is
based upon findings from a situational analysis [7,8].
Amongst other things, this key document outlines plans to
develop a portfolio of high quality, pan-African health
Addae-Mensah et al. Malaria Journal 2011, 10(Suppl 1):S9
http://www.malariajournal.com/content/10/S1/S9
Page 2 of 4
product R&D projects through direct funding and project
management; provide support for a network of research
centres of excellence as well as develop an IT platform for
knowledge management in Africa. ANDI will also broker
relationships with key stakeholders and funders through
advocacy and the fostering of project partnerships between
the public and private sectors.
Highlights of the Nairobi meeting included the inau-
guration of the ANDI Board, launch of the first call for
projects and the launch of the ANDI R&D and Knowl-
edge Management Databases. During the meeting a
round-table session on traditional medicines brought
together several experts who provided their perspectives
with further insight from the audience. The goal of the
discussion was to specifically address the opportunities
and issues related to Traditional Medicines (TM)
including plant-derived anti-malarials. These include:
• The need to better define the processes for R&D on
Traditional Medicine (TM), including validating pro-
cesses to ensure safety, efficacy and efficiency and devel-
oping a scientific rationale for each product.
• Need for policy and guidelines in the development of
TM products in Africa
• Ethical and regulatory issues on TM
• Establishment of a holistic intellectual property man-
agement policy that will address the intellectual property
issues arising from the use, development and commer-
cialization of traditional medicines.
• Bridging the gap between TM practitioners and
scientists.
• The role of TM in achieving MDGs in Africa.
These all point to the urgent need for a framework to
provide the necessary support in addressing these needs.
The report of the round table is being finalized for pub-
lication in due in course.
Defining a framework to address these needs
In summary, the consensus was that the African
research community requires a mechanism for translat-
ing the knowledge emerging from their research pro-
grammes into products. It is important that this
mechanism incorporates capacity building based on tan-
gible projects and local needs.
An important outcome from these discussions was the
elaboration on the context and framework that will allow
cooperation of various partners and donors to better
interact and support research efforts in Africa. Certainly,
a more product-orientated research approach led by
Africans is needed. ANDI is now increasingly highlighted
as a unique opportunity to help advance this approach, in
collaboration with Northern and other Southern partners
as well as Product Development Partnerships (PDPs)
such as Medicines for Malaria Venture (MMV), the
Drugs for Neglected Diseases Initiative (DNDi), the
Foundation for New Innovative Diagnostics (FIND) and
the Global Alliance for TB Drug Development (TB Alli-
ance). Opportunities for synergy could also be found in
several European and American funded R&D cooperative
programmes. An example is the EU ANTIMAL (for
research into anti-malarial drugs), which offers a valuable
framework for product-orientated drug discovery
research undertaken by a number of African research
groups alongside European malaria drugs researchers.
This EU-funded drugs research effort focuses on more
upstream discovery research, which in future initiatives
could be complemented by the industry-type product
development promoted through partnerships, for exam-
ple, PDPs or regional innovation networks like ANDI.
There has certainly been a renewed global interest in
TM and natural products research over the past few
years from all quarters (academics, industry, TM practi-
tioners and policy makers). Whether the use of tradi-
tional and modern medicine should be harmonized in
Africa to ensure the development of safe, effective and
affordable products, and whether the development of
TM-based products should follow the classic western
R&D paradigm is a debate that will continue. However,
all are in agreement that the time has come for African
researchers and policy makers to capitalize on an area
that is widely viewed as the continent’s “competitive
advantage”. By doing so (and ensuring that this is done
in a manner that is sustainable), will hopefully provide
the much needed boost to innovation, economic and
health development on the continent.
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